Welcome to EQUITY DEVELOPMENT
The UK's longest established regulated provider of sponsored equity research.
We launched EQUITY DEVELOPMENT in 1997 becoming the first ever regulated provider of Sponsored Equity Research in the UK.
Our research teams are made up of expert analysts with deep understanding & experience in their sectors. Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).
We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.
Search for Company Research
FREE REGISTRATION
Sign up today and access the very latest company research
LOG IN
For access to all company research please
BowLeven
BowLeven is an independent upstream oil and gas company listed on AIM. BowLeven’s operations are focussed on
New CEO rapidly rebuilding company
- opportunistic First Africa buy looks promising
- senior Board appointments
- our BowLeven NAV / share now 288p
BowLeven; interim results of little relevance to share price
- NAV lowered to 392p driven by Isongo delay
- Catalysts for upward revision in valuation especially in H2 2006/ Q1 2007
- Farm-in likely H1 2006
BowLeven consolidates before resuming exploration
- Bachuo well likely uncommercial
- In light of this negative newsflow NAV lowered to 427p
- Catalysts for upward revision in valuation especially in Q4 2006/ Q1 2007
- Farm-in likely Q2 2006
- Limited drivers for a true re-rating towards our NAV in the short run.
BowLeven; over-reaction on drilling news
- Manyikebi-1; not the expected oil
- Noble Energy announce significant gas/condensate discovery to the west of Etinde
- Recaculated NAV still 733p
BowLeven; richer and stronger
- BowLeven has announced a substantial capital raising involving the issue of 8.5 million new shares at 650p/share raising £53.09m after expenses.
- The deal is still subject to the usual approval procedures and was not underwritten.
- The deal was priced at a 28% discount to our pre deal NAV and we understand the deal was substantially oversubscribed. We have adjusted our NAV calculation to take into account the increased share count and cash balance.
